A Phase 2 interventional study of Idelalisib and Rituximab in Follicular Lymphoma and Small Lymphocytic Lymphoma, sponsored by Gilead Sciences. Terminated at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-14.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing idelalisib in Lymphoma, Follicular — none open to participants now, none under way, none of them phase 3. idelalisib · Lymphoma, Follicular.
Among the 12 studies testing idelalisib in Lymphoma, Follicular, this one is the 9th largest by enrollment, is one of 2 that started in 2015, is one of 5 in phase 2, and was the 7th registered.
1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.
Browse Lymphoma, Follicular studies →None of the 12 studies testing idelalisib in Lymphoma, Follicular is open now. The open studies under Lymphoma, Follicular, anywhere →
idelalisib: first FDA approval 2014 (ZYDELIG), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 3
First in 2011; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 48 across 1,503 interventional studies indexed under Lymphoma, Follicular.
Median enrollment 18 across the 12 interventional studies. Of the 12 that completed or were terminated, 11 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 12 have an industry lead sponsor. The 6 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
17 studies in Lymphoma, Follicular by Gilead Sciences: none open now, 1 under way, 1 of them phase 3. Of 13 finished, 9 (69%) have results posted.
Among the 17 studies in Lymphoma, Follicular by Gilead Sciences, this one is the 14th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2015, is one of 4 in phase 2, and was the 12th registered.
Gilead Sciences’s Lymphoma, Follicular studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing idelalisib in Lymphoma, Follicular, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 17 in Lymphoma, Follicular:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the overall response rate (ORR) and complete response (CR) rate to treatment with idelalisib in combination with rituximab in previously untreated adults with follicular lymphoma (FL) or small lymphocytic lymphoma (SLL).
An increased rate of deaths and serious adverse events (SAEs) among participants with front-line chronic lymphocytic leukemia (CLL) and early-line indolent non-Hodgkin lymphoma (iNHL) treated with idelalisib in combination with standard therapies was observed by the independent data monitoring committee (DMC) during regular review of 3 Gilead Phase 3 studies. Gilead reviewed the unblinded data and terminated those studies in agreement with the DMC recommendation and in consultation with the US Food and Drug Administration (FDA). All front-line studies of idelalisib, including this study, were also terminated.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Idelalisib + rituximab for up to 104 weeks
Drug: Idelalisib · Biological: Rituximab
150 tablets administered orally twice daily
Also known as: Zydelig®, GS-1101
375 mg/m\^2 administered intravenously (weekly for 4 weeks and then every 8 weeks from Week 12 up to Week 100)
Also known as: Rituxan®, MabThera®
Overall Response Rate
Overall response rate (ORR) was defined as the proportion of participants who achieve a confirmed complete or partial response during idelalisib treatment. ORR was to be assessed by an independent review committee (IRC).
Overall Safety Profile of Idelalisib as Measured by the Incidence of Adverse Events (AEs), Severe AEs (SAEs), AEs Leading to Idelalisib (IDL) Interruption, Idelalisib Dose Reduction, Premature Discontinuation of Idelalisib, or Death
Time frame: Up to 24 weeks plus 30 days
Rate of Grade ≥ 3 Transaminase Elevations Based on Laboratory Findings
The rate of Grade ≥ 3 transaminase elevations was defined as the number of participants with any Grade 3 or 4 alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevations.
Time frame: Up to 24 weeks plus 30 days
Idelalisib Trough and Peak Plasma Concentrations
Time frame: Predose and 1.5 hour postdose at Weeks 2, 4, and 12
Time to Response
Time to response was defined as the the interval from the start of idelalisib treatment to the first documentation of complete or partial response.
Duration of Response
Duration of response (DOR) was defined as the interval from the first documentation of complete response or partial response to the earlier of the first documentation of disease progression or death from any cause.
Progression-Free Survival
Progression-free survival (PFS) was defined as the interval from the start of idelalisib treatment to the earlier of the first documentation of disease progression or death from any cause.
Overall Survival
Overall survival was defined as the interval from enrollment to death from any cause.
Changes in Health-Related Quality of Life
Changes in health-related quality of life was to be reported by participants using the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) questionnaire.
Participants were enrolled at study sites in the United States. The first participant was screened on 14 September 2015. The last study visit occurred on 03 May 2016.
| Milestone | Idelalisib + Rituximab |
|---|---|
| Started | 10 |
| Completed | 0 |
| Not completed | 10 |
| Withdrew: Study terminated by sponsor | 9 |
| Withdrew: Adverse event | 1 |
Overall response rate (ORR) was defined as the proportion of participants who achieve a confirmed complete or partial response during idelalisib treatment. ORR was to be assessed by an independent review committee (IRC).
No measurements were reported for this outcome.
| percentage of participants | Idelalisib + Rituximab |
|---|---|
| Any AE | 90.0 |
| Any SAEs | 30.0 |
| Any AE Leading to Idelalisib Interruption | 60.0 |
| Any AE Leading to Idelalisib Dose Reduction | 30.0 |
| Any AE Leading to Premature Discontinuation of IDL | 10.0 |
| Any AE Leading to Death | 0 |
The rate of Grade ≥ 3 transaminase elevations was defined as the number of participants with any Grade 3 or 4 alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevations.
| percentage of participants | Idelalisib + Rituximab |
|---|---|
| Any Grade 3 or 4 ALT Elevation | 40.0 |
| Any Grade 3 or 4 AST Elevation | 10.0 |
| ng/mL | Idelalisib + Rituximab |
|---|---|
| Week 2 predose | 216.2 ± 161.73 |
| Week 2 1.5 hours postdose | 2240.0 ± 880.03 |
| Week 4 predose | 347.4 ± 365.57 |
| Week 4 1.5 hours postdose | 2084.3 ± 1346.26 |
| Week 12 predose | 290.5 ± 373.08 |
| Week 12 1.5 hours postdose | 1313.1 ± 1474.87 |
Time to response was defined as the the interval from the start of idelalisib treatment to the first documentation of complete or partial response.
No measurements were reported for this outcome.
Duration of response (DOR) was defined as the interval from the first documentation of complete response or partial response to the earlier of the first documentation of disease progression or death from any cause.
No measurements were reported for this outcome.
Progression-free survival (PFS) was defined as the interval from the start of idelalisib treatment to the earlier of the first documentation of disease progression or death from any cause.
No measurements were reported for this outcome.
Overall survival was defined as the interval from enrollment to death from any cause.
No measurements were reported for this outcome.
Changes in health-related quality of life was to be reported by participants using the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) questionnaire.
No measurements were reported for this outcome.
Collected over Baseline up to the last dose date plus 30 days (maximum: 24.1 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Idelalisib + Rituximab | 0/10 (0%) | 3/10 (30%) | 9/10 (90%) |
| Event | Idelalisib + Rituximab |
|---|---|
| Oedema peripheralGeneral disorders | 1/10 |
| SepsisInfections and infestations | 1/10 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 1/10 |
| Trigeminal neuralgiaNervous system disorders | 1/10 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 1/10 |
| Event | Idelalisib + Rituximab |
|---|---|
| Alanine aminotransferase increasedInvestigations | 5/10 |
| Aspartate aminotransferase increasedInvestigations | 5/10 |
| Infusion related reactionInjury, poisoning and procedural complications | 4/10 |
| NeutropeniaBlood and lymphatic system disorders | 3/10 |
| DiarrhoeaGastrointestinal disorders | 3/10 |
| VomitingGastrointestinal disorders | 3/10 |
| FatigueGeneral disorders | 3/10 |
| Acute kidney injuryRenal and urinary disorders | 3/10 |
| RashSkin and subcutaneous tissue disorders | 3/10 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 3/10 |
Intent-to-Treat (ITT) Analysis Set: all participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Idelalisib + Rituximab |
|---|---|
| Mean | 69 ± 11.7 |
| Sex: Female, Male(Participants) | Idelalisib + Rituximab |
|---|---|
| Female | 6 |
| Male | 4 |
| Ethnicity (NIH/OMB)(Participants) | Idelalisib + Rituximab |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 10 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Idelalisib + Rituximab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 10 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
No publications or documents are linked to this record.
Ran from Sep 2015 to primary completion in Apr 2016, 6 months.
Results were first posted in May 2017, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Idelalisib · Rituximab